Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Assets (2016 - 2025)

Sangamo Therapeutics has reported Other Non-Current Assets over the past 16 years, most recently at $871000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $871000.0 for Q4 2025, down 41.93% from a year ago — trailing twelve months through Dec 2025 was $871000.0 (down 41.93% YoY), and the annual figure for FY2025 was $871000.0, down 41.93%.
  • Other Non-Current Assets for Q4 2025 was $871000.0 at Sangamo Therapeutics, down from $890000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for SGMO hit a ceiling of $17.4 million in Q2 2023 and a floor of $871000.0 in Q4 2025.
  • Median Other Non-Current Assets over the past 5 years was $1.5 million (2021), compared with a mean of $4.1 million.
  • Peak annual rise in Other Non-Current Assets hit 1062.53% in 2023, while the deepest fall reached 91.28% in 2023.
  • Sangamo Therapeutics' Other Non-Current Assets stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then fell by 15.67% to $1.3 million in 2023, then increased by 18.58% to $1.5 million in 2024, then plummeted by 41.93% to $871000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $871000.0 (Q4 2025), $890000.0 (Q2 2025), and $882000.0 (Q1 2025) per Business Quant data.